Results 141 to 150 of about 35,703 (223)
Low-density lipoprotein cholesterol lowering therapies: what is on the horizon? [PDF]
, 2015 Elevated low-density lipoprotein cholesterol (LDL-C) levels are associated with an increased risk for cardiovascular disease (CVD). Statins have been the cornerstone of lipid therapy to lower LDL-C for the past two decades, but despite significant ...
Figueredo, M.D., Vincent M +1 more
core +1 more source
Journal of the American College of Cardiology, 2017 Mark A. Hlatky, Dhruv S. Kazi
openaire +2 more sources
From PK/PD to QSP: Understanding the Dynamic Effect of Cholesterol-Lowering Drugs on Atherosclerosis Progression and Stratified Medicine [PDF]
, 2016 Current computational and mathematical tools are demonstrating the high value of using systems modeling approaches (e.g. Quantitative Systems Pharmacology) to understand the effect of a given compound on the biological and physiological mechanisms ...
Diaz-Zuccarini, V, Pichardo-Almarza, C
core
The Sirt1 activator SRT3025 provides atheroprotection in Apoe−/− mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression [PDF]
, 2017 Aims The deacetylase sirtuin 1 (Sirt1) exerts beneficial effects on lipid metabolism, but its roles in plasma LDL-cholesterol regulation and atherosclerosis are controversial.
Arsiwala, Tasneem +17 more
core
Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 2437-2442, March 2026.
Fen Long +7 more
wiley +1 more source
Beyond lipids: Systemic effects of lipoprotein apheresis
Transfusion, Volume 66, Issue 3, Page 590-598, March 2026.
Menatalla Nadim, Yamac Akgun
wiley +1 more source
Integrating pharmacovigilance signals with real-world validation: a study on neurological events associated with PCSK9 inhibitors. [PDF]
Front Med (Lausanne)Zhu B, Shao Q, Cui J, Fu Z, Ma Y.
europepmc +1 more source
Blood PCSK9 Impacts Alzheimer's Disease Risk in an <i>APOE</i> Genotype-Dependent Manner: A Prospective Cohort Study. [PDF]
Health Sci RepTao Q +10 more
europepmc +1 more source